Boston Scientific, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Matson from Needham reiterated a Buy rating on the stock and has a $121.00 price target.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Michael Matson has given his Buy rating due to a combination of factors that highlight Boston Scientific’s strong position in the med tech industry. The company is expected to provide significant updates during its upcoming investor day, which include insights into its business units, recent product launches, and future product pipeline. Additionally, Boston Scientific’s recent acquisitions and long-term financial targets, such as revenue growth and operating margin improvements, further bolster confidence in its future performance.
Matson anticipates that the company’s guidance for 2026-2028 will align closely with consensus estimates, with a potential increase in organic revenue growth due to an improved weighted average market growth rate and multiple growth drivers. This outlook, combined with Boston Scientific’s reputation as a high-quality large-cap med tech company, underpins the Buy rating, suggesting that the stock is poised for continued success and value generation.
According to TipRanks, Matson is an analyst with an average return of -4.7% and a 40.96% success rate. Matson covers the Healthcare sector, focusing on stocks such as TransMedics Group, Boston Scientific, and Merit Medical Systems.